Q-omics provides the consensus-scored SNHG15 profile across patient tissues and cancer cell-line models. SNHG15 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNHG15 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SNHG15 RNA expression shows 17,992 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where SNHG15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG15 survival associations across molecular data types. SNHG15 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG15 RNA expression–survival associations across cancer types. High SNHG15 expression shows unfavorable associations in KIRC, ACC, LIHC, KICH and UVM, but favorable associations in CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNHG15 RNA expression.
This table summarizes SNHG15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG15 shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, KIRP, STAD and HNSC. The COAD box plot shows higher SNHG15 RNA expression in tumor versus normal tissue (log2 FC = +2.130, t-test p < 0.001).
This table shows molecular features associated with SNHG15 in patient tissues and cancer cell lines. In patient samples, SNHG15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
